Business Context and Reporting Period
This Form 8-K Current Report was filed by OptimizeRx Corporation (OPRX) on January 10, 2025, covering events occurring on January 3, 2025. The filing addresses the formal departure of William J. Febbo from his roles as Chief Executive Officer and Board Member, effective December 31, 2024.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and separation terms.
- Separation Compensation: Mr. Febbo is entitled to an 18-month continuation of his $450,000 annual base salary.
- Bonus Payment: A one-time lump sum payment of $450,000 representing his annual cash bonus target.
- Benefits: Reimbursement of COBRA premiums for health, dental, and vision coverage for 12 months.
- Equity: Previously granted equity will continue to vest in the ordinary course during a 3-month advisory period ending March 31, 2025.
Material Changes
The primary material change is the leadership transition involving the CEO and a Board Director. Mr. Febbo has entered into a Separation and Advisory Agreement which includes a 3-month advisory role. Additionally, the agreement enforces a 12-month non-compete and non-solicitation clause regarding employees, customers, and collaborators.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or management commentary regarding future business performance. The primary contingency noted is that Mr. Febbo has seven days to revoke his acceptance of the Separation and Advisory Agreement. The agreement is also subject to the terms of a Business Protection Agreement regarding non-competition.
Investor Verification Checklist
- Verify the appointment of an interim or permanent CEO to replace William J. Febbo.
- Confirm the total cash outflow impact of the separation package ($450,000 bonus + 18 months of salary + benefits).
- Review the attached Exhibit 10.1 (Separation and Advisory Agreement) for full legal terms.
- Monitor for any revocation of the agreement by Mr. Febbo within the 7-day window.